Evidence map›Paper›PMID 37298156›Full record

ArticleInternational journal of molecular sciences2023

Safety and Efficacy of Intravenous and Intrathecal Delivery of AAV9-Mediated ARSA in Minipigs.

Aysilu Mullagulova, Alisa Shaimardanova, Valeriya Solovyeva, Yana Mukhamedshina, Daria Chulpanova, Alexander Kostennikov, Shaza Issa, Albert Rizvanov

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Neurodegenerative Diseases in Children: A Comprehensive Review.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Adeno-Associated Viral Vectors in the Treatment of Epilepsy.International journal of molecular sciences · 2024
    Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Aysilu MullagulovaInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Alisa ShaimardanovaInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Valeriya SolovyevaInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-8776-3662
Yana MukhamedshinaInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Daria ChulpanovaInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0001-5546-840X
Alexander KostennikovInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Shaza IssaInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-1690-0199
Albert RizvanovInstitute for Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-9427-5739
Kazan Federal University · RUKazan State Medical University · RUSt Petersburg University · RU

Funding

Kazan Federal University No FZSM-2023-0011
6 · The paper itself

Abstract

Metachromatic leukodystrophy (MLD) is a hereditary neurodegenerative disease characterized by demyelination and motor and cognitive impairments due to deficiencies of the lysosomal enzyme arylsulfatase A (ARSA) or the saposin B activator protein (SapB). Current treatments are limited; however, gene therapy using adeno-associated virus (AAV) vectors for ARSA delivery has shown promising results. The main challenges for MLD gene therapy include optimizing the AAV dosage, selecting the most effective serotype, and determining the best route of administration for ARSA delivery into the central nervous system. This study aims to evaluate the safety and efficacy of AAV serotype 9 encoding ARSA (AAV9-ARSA) gene therapy when administered intravenously or intrathecally in minipigs, a large animal model with anatomical and physiological similarities to humans. By comparing these two administration methods, this study contributes to the understanding of how to improve the effectiveness of MLD gene therapy and offers valuable insights for future clinical applications.

Indexed as

Leukodystrophy, MetachromaticNeurodegenerative DiseasesAnimalsCentral Nervous SystemCerebroside-SulfataseEsterasesHumansSwineSwine, MiniatureCerebroside-SulfataseEsterasesadeno-associated virusarylsulfatase Acentral nervous systemgene therapymetachromatic leukodystrophyneurodegenerationperipheral nervous system

Identifiers

PMID37298156
PMCPMC10253118
OpenAlexW4378228143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.